Feldman B F, Handagama P, Lubberink A A
J Am Vet Med Assoc. 1985 Sep 15;187(6):617-9.
Splenectomy was done in 9 dogs having immune-mediated hematologic disorders refractory to medical therapy. These disorders were immune-mediated thrombocytopenia (n = 3), immune hemolytic anemia (n = 3), and Evan's syndrome (n = 3). The diagnoses were based on clinical observations, laboratory test data, and differential of other conditions. In the 12 months after splenectomy was done, the dogs reflected clinical improvement and return of platelet and/or erythrocyte counts to clinically acceptable limits; medical treatment was stopped or reduced in 8 of 9 patients. The exceptional patient had shown clinical improvement without change in the platelet count. At the end of 1 year, survival rate was excellent, and postsplenectomy complications, such as hemobartonellosis, did not appear. It is believed that splenectomy may be useful for treating immune-mediated thrombocytopenia, anemia, and Evan's syndrome that seem refractory to medication.
对9只患有经药物治疗难以治愈的免疫介导血液系统疾病的犬进行了脾切除术。这些疾病包括免疫介导的血小板减少症（n = 3）、免疫性溶血性贫血（n = 3）和伊文氏综合征（n = 3）。诊断基于临床观察、实验室检查数据以及对其他病症的鉴别。在脾切除术后的12个月内，这些犬的临床症状有所改善，血小板和/或红细胞计数恢复到临床可接受的范围；9只犬中有8只停止或减少了药物治疗。唯一例外的那只犬临床症状有改善，但血小板计数未发生变化。在1年末，存活率很高，且未出现脾切除术后并发症，如血巴尔通体病。据信，脾切除术可能对治疗似乎对药物治疗无效的免疫介导的血小板减少症、贫血和伊文氏综合征有用。
